Cognition Therapeutics (CGTX) Shares Outstanding (2020 - 2026)
Cognition Therapeutics (CGTX) posted quarterly Shares Outstanding (Entity) of $89.4 million for Q1 2026, up 44.18% year-over-year from $62.0 million in Q1 2025, and up 22.79% quarter-over-quarter from $72.8 million in Q4 2025.
Cognition Therapeutics (CGTX) Shares Outstanding (2020 - 2026) Analysis & Trends
Cognition Therapeutics (CGTX) has reported Shares Outstanding (Entity) for 7 consecutive years, with $89.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 44.18% year-over-year to $89.4 million; the TTM figure through Mar 2026 stood at $89.4 million (up 44.18% YoY), while the FY2025 annual figure was $72.8 million, up 83.15% from the prior year.
- Shares Outstanding (Entity) climbed to $89.4 million in Q1 2026 per CGTX's latest filing, from $72.8 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $89.4 million in Q1 2026 and bottomed at $22.6 million in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $44.3 million across 5 years, with a median of $39.7 million in 2024.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) surged 3934.92% — and 2024, when it rose 23.52%.
- Cognition Therapeutics' Shares Outstanding (Entity) stood at $23.6 million in 2022, then surged by 36.06% to $32.2 million in 2023, then increased by 23.52% to $39.7 million in 2024, then soared by 83.15% to $72.8 million in 2025, then grew by 22.79% to $89.4 million in 2026.
- Business Quant data shows CGTX's Shares Outstanding (Entity) at $89.4 million in Q1 2026, $72.8 million in Q4 2025, and $88.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Cognition Therapeutics | 90.18 Mn | 90.18 Mn | - | 90.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 90.62 Mn |
| Mar 31, 2026 | 89.19 Mn |
| Dec 31, 2025 | 72.77 Mn |
| Sep 30, 2025 | 77.95 Mn |
| Jun 30, 2025 | 63.69 Mn |
| Mar 31, 2025 | 61.83 Mn |
| Dec 31, 2024 | 39.73 Mn |
| Sep 30, 2024 | 40.42 Mn |
| Jun 30, 2024 | 40.06 Mn |
| Mar 31, 2024 | 33.74 Mn |
| Dec 31, 2023 | 30.03 Mn |
| Sep 30, 2023 | 30.37 Mn |
| Jun 30, 2023 | 29.61 Mn |
| Mar 31, 2023 | 29.09 Mn |
| Dec 31, 2022 | 23.64 Mn |
| Sep 30, 2022 | 23.02 Mn |
| Jun 30, 2022 | 22.60 Mn |
| Mar 31, 2022 | 22.43 Mn |
| Dec 31, 2021 | 5.19 Mn |
| Sep 30, 2021 | 611,680.00 |